Gilead Sciences Europe Ltd is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world.

Gilead Sciences Europe Ltd’s portfolio of products and pipeline of investigational drugs includes treatments for HIV, liver diseases, cancer and inflammatory and respiratory diseases.

Our portfolio of marketed products includes a number of category firsts. We were the first to partner with another company to develop a complete treatment regimen for HIV infection available in a once-daily single pill and we provided the first oral antiretroviral pill licensed to reduce the risk of acquiring HIV infection in certain high-risk adults.

Strength Through Partnership

Collaborations of all kinds – with partners in science, academia, business and local communities – are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.

Growing Worldwide Reach

Gilead was founded in 1987 in Foster City, California. Since then, we have grown to become one of the world’s largest biopharmaceutical companies, with more than 11,000 employees across six continents.

Questions for reporting safety information

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting scheme: www.fagg-afmps.be .

Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via email: Benelux.safety@gilead.com

Disclaimer: Images on this website are stock photos posed by models.